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Abstract
Background: It is well recognized that colorectal cancer does not frequently metastasize to bone.
The aim of this retrospective study was to establish whether colorectal cancer ever bypasses other
organs and metastasizes directly to bone and whether the presence of lung lesions is superior to
liver as a better predictor of the likelihood and timing of bone metastasis.
Methods: We performed a retrospective analysis on patients with a clinical diagnosis of colon
cancer referred for staging using whole-body 18F-FDG PET and CT or PET/CT. We combined PET
and CT reports from 252 individuals with information concerning patient history, other imaging
modalities, and treatments to analyze disease progression.
Results: No patient had isolated osseous metastasis at the time of diagnosis, and none developed
isolated bone metastasis without other organ involvement during our survey period. It took
significantly longer for colorectal cancer patients to develop metastasis to the lungs (23.3 months)
or to bone (21.2 months) than to the liver (9.8 months). Conclusion: Metastasis only to bone
without other organ involvement in colorectal cancer patients is extremely rare, perhaps more
rare than we previously thought. Our findings suggest that resistant metastasis to the lungs predicts
potential disease progression to bone in the colorectal cancer population better than liver
metastasis does.
Background
Colorectal cancer remains the third most common cancer
among adult men and women in the United States and
the third most common cause of death from cancer [1,2].
It is well accepted that colorectal cancers metastasize to
the liver and lungs more frequently than to bone or other
organs [2]. This pattern of involvement has been attrib-
uted both to the pattern of blood flow from the colon to
the portal system and to molecular signal proteins inher-
ent to the microcosm of each organ system; however;
whether one component is more important than the other
is still under debate [2-4]. Many studies have focused on
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characterizing which organ systems are most affected by
colorectal cancer metastasis; however, it remains unclear
whether there is a specific temporal pattern for metastasis.
If isolated bone metastasis is truly rare in colorectal cancer
patients, then clinicians can be very conservative in evalu-
ating a suspected bone lesion without other organ
involvement. Because bone metastasis often indicates the
terminal phase of colon cancer, clinicians should be more
vigilant about possible bone metastasis in colorectal can-
cer patients with lung metastasis.
The aim of this retrospective study was to establish
whether colorectal cancer can bypass other organs and
metastasize directly to bone and whether lung metastasis
is better than liver metastasis for predicting whether and
when bone involvement develops. In addition to deter-
mining which other metastasis more effectively predicts
impending bone lesions, we determine whether the pres-
ence of liver or lung lesions correlates with the increased
likelihood and the timing of bone metastasis.
Methods
We submitted an application to The University of Texas
Medical School at Houston Institutional Review Board,
which granted us permission to access patient records for
this study from 3 outlying medical facilities. We acquired
information retrospectively and gave patient a random
numerical code for identification purposes.
We searched the serial imaging reports of all patients
referred to these outlying medical facilities from January
2000 to December 2008 with F-18-flurodeoxyglucose
(FDG)-PET in correlation with a recent CT or PET/CT and
found those with a clinical diagnosis of colon cancer. We
analyzed a total of 703 reports from colon cancer patients
(an average of 3.04 reports per patient). We attempted to
have PET and CT scans for all patients with a diagnosis of
colon cancer for staging/restaging or treatment monitor-
ing. Some colon cancer patients never had PET/CT scans
because of variable clinical issues or insurance status and
these patients were not included in this study. Stage of the
patients ranged from stage I to stage IV. We excluded
patients if they had a second primary cancer. Thus, we
included 252 patients with a primary diagnosis of color-
ectal cancer in this retrospective study. This group con-
tained 122 female patients (48.4%) and 130 male
patients (51.6%).
We included all 252 individuals when we determined
organ involvement. However, when calculating the time
and sequence of metastatic spread, we found that 21 of
the 252 patients had presented solely for initial staging
and excluded them from that analysis. The 231 individu-
als had a known date of initial diagnosis and the time of
new metastasis noted in the serial imaging reports during
the investigation. Of the 102 patients with organ metasta-
sis, 71 patients received further chemotherapy; 12 patients
received combined chemotherapy and surgery; 16
patients received combined chemotherapy and radiation
therapy; 2 patients received surgery only; and 5 patients
received no therapy. The status of treatment for 5 patients
after metastasis was uncertain. Nineteen patients devel-
oped new organ metastasis only at the end of our survey
periods. Time to development of metastatic disease was
defined as time from initial diagnosis to the appearance of
metastasis in imaging studies.
To minimize the impact of institutional variability, we
included imaging studies only if they had been read orig-
inally by 1 of 3 certified nuclear medicine radiologists.
Image Interpretation
Board-certified nuclear medicine radiologists initially
interpreted the imaging studies by using a GE Advanced
Workstation for PET/CT cases or MIM vista fusion pro-
gram (MIM vista Corp) to analyze PET and CT images
before we conceived and conducted this study. Another
individual subsequently extracted information from the
reports to include in this study. Metastases to the liver,
lungs, and bone were recorded. Because PET has low sen-
sitivity for detecting brain tumors, we did not assess brain
metastases. Disease progression was documented when
an imaging report showed involvement of a new organ
system. If a metastasis resolved after the patient received
therapy, the metastasis was still recorded based on the
date on which it was first identified by imaging.
One certified nuclear medicine radiologist reevaluated
any inconclusive or contradictory information and con-
firmed the findings if lesions were visible on subsequent
imaging studies or if other imaging modalities confirmed
the presence of the lesions. We excluded imaging studies
if we could not find a subsequent imaging report to con-
firm the lesion.
Statistics
Data were expressed as mean ± SD. We used the Microsoft
Excel 2003 to calculate the confidence intervals. We deter-
mined the statistical significance of differences by using
an unpaired 2-tailed Student t test and considered P val-
ues of less than 0.05 to be statistically significant. Because
we focused on the temporal pattern of the onset time of
organ metastasis, we did not perform Kaplan-Meier sur-
vival analysis for this study.
Results
Of the 252 patients, 55 (22%) received adjuvant local
radiation therapy and 195 (77%) underwent adjuvant
chemotherapy in addition to the surgical removal of theBMC Cancer 2009, 9:274 http://www.biomedcentral.com/1471-2407/9/274
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primary tumor. The mean patient age was 64.2 years at the
time of initial diagnosis, with a standard deviation of 11
years. The average follow-up period after diagnosis was 38
months, and 21 of 252 patients (8.3%) presented solely
for initial staging. Table 1 shows stages and therapy.
Organ involvement in the 252 patients comprised metas-
tases to the liver, lung, and bone. There was little differ-
ence between male and female patients (data not shown).
Overall, 102 of the 252 patients (40%) had organ metas-
tasis.
Sixty-three of the 252 subjects (25%) developed lung
metastasis, and 75 of 252 individuals (30%) developed
liver metastasis. Only 4 of 63 patients (6.3%) with lung
metastases had them at diagnosis, whereas 21 of the 75
(28%) with liver metastasis did (Table 2). Twenty-three of
the 63 lung metastasis patients (36.5%) developed lung
metastasis first without other organ involvement, whereas
48 of 75 patients (64%) had colorectal cancer that metas-
tasized to the liver without first involving other organs.
Forty-nine of the 63 lung metastasis patients (77.8%) had
concurrent other metastases, whereas 42 of the 75 liver
metastasis patients (56%) did. Fourteen of the 63 subjects
(22%) with lung metastasis remained free of metastasis to
other organs during follow-up, whereas 33 of the 75
patients (44%) with liver metastasis did. Only 2 individu-
als developed lung metastasis before subsequent liver
metastasis, whereas others showed lung infiltration more
slowly, years after initial diagnosis.
Analysis of metastasis to bone showed 14 of the 252 indi-
viduals (5.5%) had bone lesions and no individuals had
metastasis only to bone at the time of diagnosis. No
patient developed bone metastasis without liver and/or
lung metastasis. One individual presented with bone
lesions at the time of diagnosis; however, liver metastasis
was also present.
Of the 14 patients with lesions to bone, 8 (57%) had both
liver and bone involvement, whereas 10 (71%) had lung
metastasis. Fifty-three of the 63 patients (84%) with lung
lesions remained free of metastasis to bone during follow-
up. Similarly, 63 of the 75 patients (84%) with liver
metastasis also remained free of metastasis to bone during
follow-up.
The average time from initial diagnosis to detection of
metastatic disease was 9.8 months (± 14.9, confidence
interval [CI] 6.2–13.3) for liver involvement, significantly
shorter than the average times of 23.3 months (± 25.3, CI
16.4–30.1) to detect lung metastasis and 21.2 months (±
18.5, CI 11.2–31.3) to detect metastasis to bone (Table 3),
P < 0.05. The average time for colon cancer to metastasize
from the liver to bone was 8.3 months (± 13.4, CI 0.6–
15.9), whereas the time to metastasize from lung to bone
was 3.3 months (± 4.2, CI 0.7–5.9). However, this differ-
ence is not significant because of the small sample size.
Among the 8 patients who exhibited metastases to liver,
lungs, and bone, the average time for the cancer to metas-
tasize from the liver to bone was also longer than the time
for the cancer to metastasize from the lung to bone (6.0
months ± 11.1 versus 4.3 months ± 6.1). However, the
results are not statistically significant. On average,
involvement was detected in all 3 organs within 30
months of the original diagnosis of colon cancer.
Of the 14 patients with metastasis to bone, 2 were still
alive, 2 were lost to follow-up, and 8 were dead by the end
of this study. The average time from when bone involve-
ment was detected until the patient died was 15.9 months
(± 13.2, CI 6.7–25.1), and the average lifespan of patients
with bone metastasis after initial diagnosis of colorectal
cancer was 42.4 months (± 18.1, CI 29.8–54.9).
Discussion
Analysis of Involvement in Bone
This study determined that despite individual variance in
the degree and order of organ involvement among
patients with colorectal cancer, a general temporal pattern
does exist. Malignancies never spread primarily to bone.
This is a characteristic particular to colorectal cancer as
bone metastasis is far more frequent in the other leading
cancer types. Although clinicians still cannot agree on the
prevalence of breast, lung, and prostate cancers metastasis
only to bone is a common occurrence in these cancers [5].
One study even postulated that as many as 70% of
patients with stage IV breast cancer have bone involve-
ment [6]. By contrast, cancer typically metastasizes to
bone in less than 10% of colorectal cancer patients [7].
This suggests that colon cancer behaves differently with
respect to bone metastasis compared with other cancers.
Our study results also confirm this unique behavior. No
cancer metastasized to bone without first metastasizing to
Table 1: Demographic information of the survey population
Parameter Number (percentage)
Age (mean ± SD) 64.2 year ± 11
Initially staged as I to III 216/252 (86)
Initially staged as IV 36/252 (14)
Primary cancer surgery 206/231 (89)
Adjuvant radiation therapy 55/231 (23.8)1
Adjuvant chemotherapy 195/231 (84.4)1
Total metastasis to liver, lung, or bone 102/252 (40)
SD = Standard deviation
1 The denominator is the 21 patients seen only for initial staging 
subtracted from the total number of patients.BMC Cancer 2009, 9:274 http://www.biomedcentral.com/1471-2407/9/274
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the liver or lung in our study. This finding contrasts with
a previous study on bone metastasis in colorectal cancer
patients by Kanthan et al [8] in which 1.1% of colorectal
cancer population developed isolated metastasis. How-
ever, that study used bone scans and plain radiography to
detect lesions, and both methods have low specificity that
may overestimate the actual incidence of bone metastasis.
This possibility was demonstrated during our data acqui-
sition, when PET/CT disproved the findings of a positive
bone scan in the pelvis, by demonstrating that there was
no indication of bone metastasis on either PET or CT scan.
Patient's remote history of pelvic fracture probably led to
the false positive result of the bone scan (Figures 1 and 2).
Another case that originally appeared as bone metastasis
to the pelvis on a bone scan was identified as local/direct
tumor invasion into the sacrum on the PET and CT scans
(data not shown).
It is also likely that the higher sensitivity and specificity of
PET and CT for detecting early metastasis in liver and lung
compared with traditional radiography may account for
the strong correlation among lesions to the liver, lung,
and bone in our study. Possibly, concurrent involvement
of other organs did exist but went undetected in the
patients who had only bone lesions in the Kanthan et al
study [8]. However, confirming whether the complete
absence of true isolated bone metastasis is characteristic of
colorectal cancer will require a larger study population.
This study sought to identify whether disease progression
to the lungs could predict metastasis to bone. Although
lung lesions are of particular interest as a forerunner of
future bone metastasis as evidenced by the short time
span from lung metastasis to bone involvement, the
lesions in bone always appear after metastasis to liver,
lung, or (in a large percentage) both. As the average 5-year
survival rate of colon cancer patients with metastasis to
bone continues to be 8.1% [9], and on average, 67% of
those who developed bone involvement during this sur-
vey were dead 16 months after detection of bone metasta-
sis, the importance of recognizing disease progression and
potential significance of bone metastasis cannot be over-
emphasized.
Disease Progression
The findings in this study regarding colon cancer metasta-
sis to the bone and lungs correlate with results in the cur-
rent literature. Our findings of lung metastasis in 25% of
patients and bone metastasis in 5.5% of patients concur
with the results from other studies [2,8]. As reported in the
literature that colorectal cancer metastasizes first to the
liver or lungs, which both contain dense capillary beds
that can trap tumor cells and seed them into these organs
[3]. The environment of a specific organ and its influence
on tumor cell adhesion can also contribute to the efficacy
of tumor spread, which occurs in colorectal cancer
patients most frequently in the liver and lungs [2,3].
However, the 30% incidence of liver metastasis in our
study is much lower than the incidence of liver metastasis
in earlier studies, which reported liver involvement in 70–
83% of patients [2,8]. The lower incidence of liver lesions
detected in this study may be due to patient selection,
because clinicians had resected the primary tumors in
most of our patients and were monitoring them to evalu-
ate possible recurrence during the investigation. During
the study period, 44% of those who developed liver
metastasis remained free of other organ metastasis, and
84% had liver lesions that never progressed to bone.
The percentage of metastatic lung involvement in our
study correlates with that reported in the literature. How-
ever, unlike people with liver lesions, 78% of people with
lung lesions showed concurrent disease involvement in
Table 2: Colorectal cancer organ metastases in certain criteria
Patient Number (Percentage)
Organ Metastasis Total metastasis At initial diagnosis Concurrent with other metastasis As the first site of organ metastasis
Liver 75/252 (30) 21/75 (28) 42/75 (56) 48/75 (64)
Lung 63/252 (25) 4/63 (6.3) 49/63 (77.8) 23/63 (36.5)
Bone 14/252 (5.5) 1/14 (7.1) 14/14 (100) 0/14 (0)
Table 3: Average time (months) to organ metastasis in 
metastatic colon cancer patients
Type of Metastasis Time ± SD Patients1
Liver metastasis 9.8 ± 14.9 54
Lung metastasis 23.3 ± 25.32 59
Bone metastasis 21.2 ± 18.52 13
From liver metastasis to bone metastasis 8.3 ± 13.4 12
From lung metastasis to bone metastasis 3.3 ± 4.23 10
SD = standard deviation.
1 Patients with only 1 scan are not included in these calculations.
2 A significant difference (unpaired Student t test, P < 0.05) was found 
when the time to metastasis from the colon to the lung or bone was 
compared with the time to metastasis from the colon to the liver.
3 No significant difference (P > 0.05) was found when the time from 
lung metastasis to bone metastasis was compared with the time from 
liver metastasis to bone metastasis.BMC Cancer 2009, 9:274 http://www.biomedcentral.com/1471-2407/9/274
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other organs. When combined with the temporal differ-
ence between the time from liver metastasis to bone
metastasis and the time from lung metastasis to bone
metastasis, this finding suggests that lung metastasis indi-
cates refractory, potentially serious disease more precisely
than liver metastasis does. Most lung and liver metastases
that we observed consisted of multiple lesions. However,
solitary lesion occurred more often in the liver than that
in the lung.
Although this study attempted to uncover the relationship
between the pattern of disease progression and the devel-
opment of bone metastasis, the resulting subpopulation
of patients with metastasis to bone was small, and most
had diffuse involvement of multiple organs at the same
time point. Thus, further studies with a larger patient pop-
ulation with more frequent imaging studies are necessary
to ascertain whether the order of organ involvement has
any impact on the development of bone metastasis.
Lymphatic spread and local recurrence were excluded
from analysis in this study because most patients had
undergone local resection with local lymph node dissec-
tion before their staging work-up. Further investigation of
the possible relationship between the nodal spread of dis-
ease, including local or distant nodal metastasis and
metastasis to bone in a different patient population set-
ting, would be interesting. After cancer cells break through
the defense barrier of the lymphatic system, especially
those lymph nodes outside the portal system, the cancer
may metastasize more readily to the lungs and bone. We
did not analyze brain metastasis because of the low sensi-
tivity of PET for brain tumor detection and our PET/CT
imaging protocol does not include the brain.
Strengths
A strength of this study is that it included a systematic
approach to evaluate disease progression. Using the files
of 3 nuclear medicine radiologists facilitated the creation
of a large database that spanned institutions, widened
demographics, and maintained quality and consistency in
the imaging reports.
In addition, unlike most studies that have characterized
colorectal cancer metastasis, we used PET and CT, which
are newer and more sensitive tools to detect colon cancer
metastasis, rather than less precise methods like tradi-
tional radiography or bone scintigraphy [8]. Our results
are therefore a direct reflection of what diagnosticians can
expect to see when staging a colorectal cancer patient
using current technology.
Drawbacks
A major limitation of this study is the retrospective nature.
We obtained the imaging studies during staging and sub-
Bone scan posterior view of a 54-year-old woman with a 2- year history of recurrent colon cancer revealed a focal tracer  uptake in the right sacroiliac joint area suggesting possible  bone metastasis Figure 1
Bone scan posterior view of a 54-year-old woman 
with a 2-year history of recurrent colon cancer 
revealed a focal tracer uptake in the right sacroiliac 
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sequent follow-up by using a combination of PET with
correlation of a recent CT and PET/CT. In addition, the
imaging modality at each time point varied among
patients and we only followed the patients during the
imaging periods because of the retrospective nature of the
study.
Most of the patients from the 3 outlying medical facilities
experienced surgical resection of the primary tumor along
with removal of neighboring lymph nodes before they
had a detailed staging work-up. This patient population
therefore may not be representative of general colorectal
patients.
Conclusion
The main implication of this study for clinicians is that if
a colorectal cancer patient has no sign of disease involve-
ment in the liver or lungs, evaluation of a suspicious bone
lesion should not be aggressive, but should obtain more
noninvasive data from other diagnostic modalities or fol-
low-up.
Lung metastasis indicates the potential for cancer to
metastasize to bone in the colorectal cancer population
better than liver metastasis does.
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FDG PET/CT scan of the same patient in Figure 1 revealed  no focally increased FDG uptake or suspicious abnormalities  to bone on the CT of the right sacroiliac area to correspond  the bone scan findings (short arrows) Figure 2
FDG PET/CT scan of the same patient in Figure 1 
revealed no focally increased FDG uptake or suspi-
cious abnormalities to bone on the CT of the right 
sacroiliac area to correspond the bone scan findings 
(short arrows). The patient's history of pelvic fracture 
probably explained the focal tracer uptake in bone scan. The 
recurrent colon cancer in the left pelvis observed by both 
PET and CT scans is marked by the long arrows.